<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711413892</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711413892</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Comment</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prognostic Value of Mean Platelet Volume in Patients With Non-ST-Elevation Acute Coronary Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>López-Cuenca</surname>
<given-names>Angel A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413892">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tello-Montoliu</surname>
<given-names>Antonio</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0003319711413892">2</xref>
<xref ref-type="aff" rid="aff3-0003319711413892">3</xref>
<xref ref-type="corresp" rid="corresp1-0003319711413892"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roldán</surname>
<given-names>Vanessa</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff4-0003319711413892">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pérez-Berbel</surname>
<given-names>Patricio</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319711413892">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Valdés</surname>
<given-names>Mariano</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413892">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marín</surname>
<given-names>Francisco</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711413892">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711413892"><label>1</label>Cardiology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain</aff>
<aff id="aff2-0003319711413892"><label>2</label>Cardiology Department, Hospital General Universitario Alicante, Alacant, Spain</aff>
<aff id="aff3-0003319711413892"><label>3</label>Department of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, Shands Jacksonville, Jacksonville, FL, USA</aff>
<aff id="aff4-0003319711413892"><label>4</label>Hematology and Clinical Oncology Department. Hospital Universitario Morales Meseguer, University of Murcia, Murcia, Spain</aff>
<author-notes>
<corresp id="corresp1-0003319711413892">Antonio Tello-Montoliu, Department of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, Shands Jacksonville, 655 West 8th Street, Jacksonville, FL 32209, USA Email: <email>Antonio.Tello@jax.ufl.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>4</issue>
<fpage>241</fpage>
<lpage>244</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The aim of this study is to determine mean platelet volume (MPV) in a population with non-ST-elevation acute coronary syndrome (nSTEACS) and explore its relation with prognosis. Patients (n = 329) with a diagnosis of nSTEACS at admission were recruited, with a determination of MPV in the first 12 hours at admission. We also collected blood from 87 healthy controls. A composite end point of cardiovascular death and new ACS was assessed at 6-month follow-up. Patients with nSTEACS showed larger platelets (MPV: 11.0 [10.3-11.8] vs 9.2 [8.6-10.0] fL; <italic>P</italic> &lt; .001.). In Cox regression analysis, MPV at admission was a significant predictor of cardiovascular adverse events in univariate analysis, hazard ratio (HR) 1.4 95% confidence interval (CI) 1.1-1.8; <italic>P</italic> = .018; but after adjustment with clinical variables, MPV lost its statistical significance. In conclusion, patients with nSTEACS present with larger platelets than healthy controls, however this parameter did not show an independent prognostic significance at 6-month follow-up.</p>
</abstract>
<kwd-group>
<kwd>MPV</kwd>
<kwd>acute coronary syndrome</kwd>
<kwd>platelets</kwd>
<kwd>prognosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711413892">
<title>Introduction</title>
<p>Activated platelets play a pivotal role in atherothrombosis, the major cause of most acute coronary syndromes (ACS). However, patients with different presentations of ACS (ST-elevation myocardial infarction [STEMI] or unstable angina [UA]/non-ST-elevation MI [non-STEMI]) have different degrees of platelet activation<sup>
<xref ref-type="bibr" rid="bibr1-0003319711413892">1</xref>
</sup> and a heterogeneous risk of new ischemic events.<sup>
<xref ref-type="bibr" rid="bibr2-0003319711413892">2</xref>
</sup> Mean platelet volume (MPV) is the most common parameter used to measure the platelet size. It is routinely available at a relatively low cost. Larger platelets are metabolically and enzymatically more active<sup>
<xref ref-type="bibr" rid="bibr3-0003319711413892">3</xref>
</sup> and have greater prothrombotic potential.<sup>
<xref ref-type="bibr" rid="bibr4-0003319711413892">4</xref>
</sup> Higher MPV values are related to the presence of cardiovascular risk factors.<sup>
<xref ref-type="bibr" rid="bibr5-0003319711413892">5</xref><xref ref-type="bibr" rid="bibr6-0003319711413892"/><xref ref-type="bibr" rid="bibr7-0003319711413892"/>–<xref ref-type="bibr" rid="bibr8-0003319711413892">8</xref>
</sup> Also, higher MPV values characterize patients with MI and UA as compared with those with stable angina or noncardiac chest pain.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711413892">9</xref>
</sup> Interestingly, previous evidence suggests that MPV may be a risk factor for recurrent MI independent of established risk factors, so it could be considered an emerging risk marker of atherothrombosis.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711413892">9</xref>
</sup> However, previous studies focused on the old definitions for ACS, mixing different risks of new events. We hypothesized that patients with non-ST elevation ACS (nSTEACS) could have large platelets (ie, higher MPV) and this proposed biomarker may predict new adverse events.</p>
</sec>
<sec id="section2-0003319711413892">
<title>Methods</title>
<p>Patients with the diagnosis of nSTEACS were included from 2 tertiary hospitals. The diagnosis of nSTEACS was made in all cases following the current guidelines.<sup>
<xref ref-type="bibr" rid="bibr2-0003319711413892">2</xref>
</sup> The therapies and management used in these patients were carried out according to current guidelines as well. We included 329 consecutive patients with nSTEACS and 87 unrelated healthy controls matched for age and sex. All participants gave their informed consent. Blood was collected from the antecubital vein in the first 12 hours after admission in emergency department, preferably at 8:00 <sc>am</sc> next morning. Blood was drawn in sodium citrated tubes and was analysed using a Symex XE-5000 (Roche Diagnostics, Basel, Switzerland). Blood samples of healthy controls were drawn at 8:00 <sc>am</sc> in fasting state, in sodium citrated tubes and sent in the same manner as for patients with nSTEACS. Thrombolysis In Myocardial Infarction (TIMI) risk score was calculated at admission in all patients and hematological parameters as well as troponin T (TnT) and MPV were collected. After discharge, a 6-month follow-up was performed using telephone contact or clinical interview. Cardiovascular adverse events (CAEs) were defined as cardiovascular death and new ACS (with or without ST elevation).</p>
<sec id="section3-0003319711413892">
<title>Statistical Analysis</title>
<p>Continuous data were checked for normality of distribution and subsequently analyzed as appropriate using unpaired <italic>t</italic> tests (normally distributed data) or Mann-Whitney tests (nonnormally distributed data). Correlations between 2 continuous variables were performed using the Pearson correlation coefficient or Spearman rank correlation, if the variables were not normally distributed. The independent effect of variables on prognosis was calculated using a Cox proportional hazards multivariable regression model, including TIMI risk scale. A 2-tailed <italic>P</italic> &lt; .05 was considered significant.</p>
</sec>
</sec>
<sec id="section4-0003319711413892">
<title>Results</title>
<p>The study cohort demographics are shown in <xref ref-type="table" rid="table1-0003319711413892">Table 1</xref>
. Briefly, 39.9% patients presented with downsloping ST and 51.9% with increased levels of TnT. TIMI risk score calculated was 3 (2-4; median, interquartile range). There was no difference in platelet count between the 2 groups (<italic>P</italic> = .208), but patients with nSTEACS showed larger platelets, MPV = 11.0 (10.3-11.8) versus 9.2 (8.6-10.0) fL; <italic>P</italic> &lt; .001. There were no differences in the values of MPV between patients with downsloping ST segment (<italic>P</italic> = .909), high TnT levels (<italic>P</italic> = .644), and those who presented with severe anginal symptoms (<italic>P</italic> = .204) compared with those not presenting them. We found a significant correlation of MPV with platelet count (<italic>r</italic> = −.24; <italic>P</italic> &lt; .001) and TIMI risk score (<italic>r</italic> = .15; <italic>P</italic> = .007).</p>
<table-wrap id="table1-0003319711413892" position="float">
<label>Table 1.</label>
<caption>
<p>Basal Characteristics<sup><xref ref-type="table-fn" rid="table-fn2-0003319711413892">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0003319711413892" xlink:href="10.1177_0003319711413892-table1.tif"/>
<table>
<thead>
<tr>
<th>N</th>
<th>392</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>67.3 ± 12.3</td>
</tr>
<tr>
<td>Male sex</td>
<td align="center">64%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>272 (69.4%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>159 (40.6%)</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>218 (55.7%)</td>
</tr>
<tr>
<td>Smoking habit (current)</td>
<td>227 (58.0%)</td>
</tr>
<tr>
<td>Prior AMI</td>
<td>68 (17.2%)</td>
</tr>
<tr>
<td>Prior stable angina</td>
<td>50 (12.7%)</td>
</tr>
<tr>
<td>Coronary revascularization (PCI/CABG)</td>
<td>67 (17.0%)</td>
</tr>
<tr>
<td>Downsloping ST</td>
<td>157 (39.9%)</td>
</tr>
<tr>
<td>High TnT levels</td>
<td>204 (51.9%)</td>
</tr>
<tr>
<td>TIMI risk score</td>
<td>3 (2-4)</td>
</tr>
<tr>
<td>Creatinine, g/dL</td>
<td>0.95 (0.80-1.13)</td>
</tr>
<tr>
<td>Leukocytes, /mm<sup>3</sup>
</td>
<td>8055 (6715-9902)</td>
</tr>
<tr>
<td>Neutrophils, /mm<sup>3</sup>
</td>
<td>5040 (3940-6760)</td>
</tr>
<tr>
<td>Lymphocytes, /mm<sup>3</sup>
</td>
<td>1950 (1420-2540)</td>
</tr>
<tr>
<td>Haemoglobin, g/dL</td>
<td>13.8 ± 1.8</td>
</tr>
<tr>
<td>Platelet count (× 1000)/mm<sup>3</sup>
</td>
<td>209 (174-252)</td>
</tr>
<tr>
<td>MPV, fL</td>
<td>11.0 (10.3-11.8)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711413892">
<p>Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery; TnT, troponinT levels (high: &gt;0.10 mg/mL); AMI, acute myocardial infarction; TIMI, Thrombolysis In Myocardial Infarction; MPV, mean platelet volume; SD, standard deviation.</p>
</fn>
<fn id="table-fn2-0003319711413892">
<p>
<sup>a</sup> Variables are expressed as mean ±SD or median (interquartile range) if they are normally or not normally distributed, respectively.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>After 6-month follow-up, 53 (16.1%) CAEs occurred: 18 cardiovascular deaths and 35 new ACS (33 with and 2 without ST-elevation). We performed a Cox regression analysis, where age more than 65 years (hazard ratio [HR]: 3.8; 95% confidence interval [CI] 1.7-8.6; <italic>P</italic> = .001), diabetes mellitus (HR: 2.1; 95% CI 1.2-3.8; <italic>P</italic> = .014), severe angina symptoms (HR: 2.2; 95% CI 1.2-3.9; <italic>P</italic> = .012), and MPV as continuous variable (HR 1.4 CI 95% 1.1-1.8, <italic>P</italic> = .018,) were significant predictors of CAE after univariate analysis. However, after adjustment for clinical variables (included in TIMI risk score), MPV lost its statistical significance. Details of the Cox regression analysis are described in <xref ref-type="table" rid="table2-0003319711413892">Table 2</xref>
.</p>
<table-wrap id="table2-0003319711413892" position="float">
<label>Table 2.</label>
<caption>
<p>Cox Regression Analysis at 6-Month Follow-Up<sup><xref ref-type="table-fn" rid="table-fn4-0003319711413892">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-0003319711413892" xlink:href="10.1177_0003319711413892-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th colspan="2">Univariate</th>
<th colspan="2">Multivariate</th>
</tr>
<tr>
<th>Variable</th>
<th>HR (95% CI)</th>
<th>
<italic>P</italic>
</th>
<th>HR (95% CI)</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 65-year-old</td>
<td>3.8 (1.7-8.6)</td>
<td>.001</td>
<td>3.6 (1.5-8.6)</td>
<td>.004</td>
</tr>
<tr>
<td>Diabetes</td>
<td>2.1 (1.2-3.8)</td>
<td>.014</td>
<td>1.4 (0.8-2.7)</td>
<td>.275</td>
</tr>
<tr>
<td>ST depression</td>
<td>1.6 (0.9-3.8)</td>
<td>.126</td>
<td>1.4 (0.7-2.6)</td>
<td>.363</td>
</tr>
<tr>
<td>TnT ≥0.1 mg/mL</td>
<td>1.6 (0.9-2.9)</td>
<td>.110</td>
<td>1.1 (0.6-2.2)</td>
<td>.823</td>
</tr>
<tr>
<td>Previous aspirin</td>
<td>1.4 (0.8-2.6)</td>
<td>.259</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td>≥50% stenosis</td>
<td>1.8 (0.9-3.2)</td>
<td>.068</td>
<td>1.5 (0.8-2.7)</td>
<td>.237</td>
</tr>
<tr>
<td>Severe symptoms</td>
<td>2.2 (1.2-3.9)</td>
<td>.012</td>
<td>1.8 (0.9-3.4)</td>
<td>.066</td>
</tr>
<tr>
<td>MPV, fL</td>
<td>1.4 (1.1-1.8)</td>
<td>.018</td>
<td>1.3 (0.9-1.7)</td>
<td>.093</td>
</tr>
<tr>
<td>MPV (4th Q), fL</td>
<td>1.8 (0.9-3.3)</td>
<td>.051</td>
<td>1.7 (0.9-3.1)</td>
<td>.108</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0003319711413892">
<p>Abbreviations: TnT, troponin T; MPV, mean platelet volume; HR, hazard ratio.</p>
</fn>
<fn id="table-fn4-0003319711413892">
<p>
<sup>a</sup> In the multivariate analysis were included these variables with <italic>P</italic> &gt; .15 in the univariate analysis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0003319711413892">
<title>Discussion</title>
<p>Our results show the different values of MPV between patients with nSTEACS in comparison with healthy controls but failed to confirm the independent prognostic value of this hematological parameter in the prediction of ischemic adverse events in a 6-month follow-up among patients with nSTEACS. Several studies have related high MPV levels to overall vascular mortality, including MI.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711413892">9</xref><xref ref-type="bibr" rid="bibr10-0003319711413892"/><xref ref-type="bibr" rid="bibr11-0003319711413892"/><xref ref-type="bibr" rid="bibr12-0003319711413892"/>–<xref ref-type="bibr" rid="bibr13-0003319711413892">13</xref>
</sup> Larger platelets, characterized by high MPV, are associated with increased platelet reactivity which represents a major risk factor for atherothrombosis.<sup>
<xref ref-type="bibr" rid="bibr3-0003319711413892">3</xref>,<xref ref-type="bibr" rid="bibr4-0003319711413892">4</xref>
</sup> Therefore, MPV has been suggested as a simple marker of functional status of platelets and may represent a risk factor for vascular adverse events. In fact, recent meta-analysis and large-scale retrospective studies showed that patients with high MPV have increased risk mainly of overall mortality.<sup>
<xref ref-type="bibr" rid="bibr10-0003319711413892">10</xref>,<xref ref-type="bibr" rid="bibr13-0003319711413892">13</xref>
</sup> In our study, there was no significant association between high MPV levels and adverse events after adjustment with TIMI risk scale. This discrepancy may be related to the heterogeneous populations included in previous studies. Previous prospective studies were performed mainly among patients with MI, using a biochemical definition of raised myocardial enzymes.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711413892">9</xref><xref ref-type="bibr" rid="bibr10-0003319711413892"/><xref ref-type="bibr" rid="bibr11-0003319711413892"/><xref ref-type="bibr" rid="bibr12-0003319711413892"/>–<xref ref-type="bibr" rid="bibr13-0003319711413892">13</xref>
</sup> Other studies have used large populations of “all comers” without specifying the characteristics of patients included in the analysis.<sup>
<xref ref-type="bibr" rid="bibr13-0003319711413892">13</xref>
</sup> Moreover, the cutoff values<sup>
<xref ref-type="bibr" rid="bibr9-0003319711413892">9</xref><xref ref-type="bibr" rid="bibr10-0003319711413892"/><xref ref-type="bibr" rid="bibr11-0003319711413892"/><xref ref-type="bibr" rid="bibr12-0003319711413892"/>–<xref ref-type="bibr" rid="bibr13-0003319711413892">13</xref>
</sup> for MPV varied in a range between 9 and 11.01 fL. It is important to highlight that in an ACS setting, the release of some acute mediators may affect the MPV value causing a transient increase during the acute phase.<sup>
<xref ref-type="bibr" rid="bibr14-0003319711413892">14</xref>
</sup> However, these mediators are not maintained long term. We were not able to address the time-dependent change in MPV, which may be useful in the understanding of the prognosis significant of this parameter. Drug effect on platelet size would be another variable affecting MPV. Indeed, clopidogrel therapy significantly inhibits the ADP-induced increase in MPV in vitro,<sup>
<xref ref-type="bibr" rid="bibr15-0003319711413892">15</xref>,<xref ref-type="bibr" rid="bibr16-0003319711413892">16</xref>
</sup> but in vitro aspirin had no effect on platelet size.<sup>
<xref ref-type="bibr" rid="bibr17-0003319711413892">17</xref>,<xref ref-type="bibr" rid="bibr18-0003319711413892">18</xref>
</sup> The situation may not be the same in vivo.<sup>
<xref ref-type="bibr" rid="bibr16-0003319711413892">16</xref>,<xref ref-type="bibr" rid="bibr18-0003319711413892">18</xref>
</sup> Lifestyle modification, antihypertensive, lipid-lowering and diet therapies can also affect MPV values, however additional data are needed to elucidate the role of these effects on the prognostic significance of MPV.<sup>
<xref ref-type="bibr" rid="bibr19-0003319711413892">19</xref>
</sup> We have not found any clinical data that show an association of MPV with various platelet inhibitors. Finally, to the best of our knowledge, no study adjusted prognostic information with the recognized (and under current use) risk scales in predicting adverse events. This study is based on patients with a particular presentation of ACS, nSTEACS, which is related with a different platelet activation and an heterogeneous risk of new ischemic events.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711413892">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319711413892">2</xref>
</sup>
</p>
<p>Several biomarkers with prognostic significance among patients with nSTEACS have been proposed. However, these novel biomarkers add relatively little prognostic information to the current risk stratification scales.<sup>
<xref ref-type="bibr" rid="bibr20-0003319711413892">20</xref>
</sup> Thus, the information related to a single biomarker should be interpreted with caution.<sup>
<xref ref-type="bibr" rid="bibr20-0003319711413892">20</xref>
</sup> A barely assumed limitation in the use of new biomarkers in prognosis prediction is the use of standard determination systems for common use in clinical practice. Thus, some discrepancies may exist among the different systems used to measure MPV, resulting in different cutoff points among previous studies.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711413892">9</xref><xref ref-type="bibr" rid="bibr10-0003319711413892"/><xref ref-type="bibr" rid="bibr11-0003319711413892"/><xref ref-type="bibr" rid="bibr12-0003319711413892"/>–<xref ref-type="bibr" rid="bibr13-0003319711413892">13</xref>
</sup> Although MPV is simple and inexpensive to obtain, a formal comparison between systems and with other markers of platelet activity is needed to fully characterize clinical utility. These observations highlight the necessity of an evaluation on the “real” prognostic information of new biomarkers in addition to current risk scales.</p>
<p>In conclusion, patients presenting with nSTEACS showed large platelet assessed by MPV. Although MPV showed a significant influence in prognosis in univariate analysis, this is lost after adjusting by an established risk score. More prospective studies are needed to evaluate the information added by MPV to the current risk scales in the different populations with ACS.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at" id="fn1-0003319711413892">
<p>This study was presented at the Congreso de las Enfermedades Cardiovasculares (Spanish Society of Cardiology annual Meeting) in Valencia (Spain), October 2010.</p>
</fn>
<fn fn-type="conflict" id="fn2-0003319711413892">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0003319711413892">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711413892">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Angiolillo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention</article-title>. <source>Clin Cardiol</source>. <year>2008</year>;<volume>31</volume>(<issue>3 suppl 1</issue>):<fpage>I17</fpage>–<lpage>I20</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711413892">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bassand</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Ardissino</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Task force for diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of European Society of Cardiology, Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>(<issue>13</issue>):<fpage>1598</fpage>–<lpage>1660</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711413892">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karpatkin</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets</article-title>. <source>J Clin Invest</source>. <year>1969</year>;<volume>48</volume>(<issue>6</issue>):<fpage>1083</fpage>–<lpage>1087</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711413892">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamath</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blann</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Lip</surname>
<given-names>GY</given-names>
</name>
</person-group>. <article-title>Platelet activation: assessment and quantification</article-title>. <source>Eur Heart J</source>. <year>2001</year>;<volume>22</volume>(<issue>17</issue>):<fpage>1561</fpage>–<lpage>1571</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711413892">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Symeonidis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Maltezos</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Mean platelet volume in patients with type 2 diabetes mellitus</article-title>. <source>Platelets</source>. <year>2004</year>;<volume>15</volume>(<issue>8</issue>):<fpage>475</fpage>–<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711413892">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nadar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blann</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Lip</surname>
<given-names>GY</given-names>
</name>
</person-group>. <article-title>Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine based antihypertensive therapy</article-title>. <source>Ann Med</source>. <year>2004</year>;<volume>36</volume>(<issue>7</issue>):<fpage>552</fpage>–<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711413892">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pathansali</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bath</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Altered megakaryocyte–platelet haemostatic axis in hypercholesterolaemia</article-title>. <source>Platelets</source>. <year>2001</year>;<volume>12</volume>(<issue>5</issue>):<fpage>292</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711413892">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kario</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matsuo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakao</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis</article-title>. <source>Clin Lab Haematol</source>. <year>1992</year>;<volume>14</volume>(<issue>4</issue>):<fpage>281</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711413892">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>PB</given-names>
</name>
<etal/>
</person-group>. <article-title>Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis</article-title>. <source>J Thromb Haemost</source>. <year>2010</year>;<volume>8</volume>(<issue>1</issue>):<fpage>148</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711413892">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huczek</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kochman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Filipiak</surname>
<given-names>KJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Mean platelet volume on admission predicts impaired reperfusion and longterm mortality in acute myocardial infarction treated with primary percutaneous coronary intervention</article-title>. <source>J Am Coll Cardiol</source>. <year>2005</year>;<volume>46</volume>(<issue>2</issue>):<fpage>284</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711413892">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burr</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Holliday</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Fehily</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Whitehead</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART)</article-title>. <source>Eur Heart J</source>. <year>1992</year>;<volume>13</volume>(<issue>2</issue>):<fpage>166</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711413892">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pabon Osuna</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nieto Ballesteros</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Morinigo Munoz</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of the mean platelet volume on the short-term prognosis of acute myocardial infarct</article-title>. <source>Rev Esp Cardiol</source>. <year>1998</year>;<volume>51</volume>(<issue>10</issue>):<fpage>816</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711413892">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slavka</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Perkmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Haslacher</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2011</year>;<volume>31</volume>(<issue>5</issue>):<fpage>1215</fpage>–<lpage>1218</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711413892">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jagroop</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Clatworthy</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lewin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy</article-title>. <source>Platelets</source>. <year>2000</year>;<volume>11</volume>(<issue>1</issue>):<fpage>28</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711413892">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jagroop</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease</article-title>. <source>Br J Haematol</source>. <year>2003</year>;<volume>120</volume>(<issue>1</issue>):<fpage>169</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711413892">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsagas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jagroop</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Geroulakos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>The effect of a loading dose (300 mg) of clopidogrel on platelet function inpatients with peripheral arterial disease</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2003</year>;<volume>9</volume>(<issue>2</issue>):<fpage>115</fpage>–<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711413892">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharpe</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Desai</surname>
<given-names>ZR</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>TC</given-names>
</name>
</person-group>. <article-title>Increase in mean platelet volume in patients with chronic renal failure treated with erythropoietin</article-title>. <source>J Clin Pathol</source>. <year>1994</year>;<volume>47</volume>(<issue>2</issue>):<fpage>159</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711413892">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jagroop</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Matsagas</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Geroulakos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease</article-title>. <source>Platelets</source>. <year>2004</year>;<volume>15</volume>(<issue>2</issue>):<fpage>117</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711413892">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasparyan</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Ayvazyan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Kitas</surname>
<given-names>GD</given-names>
</name>
</person-group>. <article-title>Mean platelet volume: a link between thrombosis and inflammation?</article-title> <source>Curr Pharm Des</source>. <year>2011</year>;<volume>17</volume>(<issue>1</issue>):<fpage>47</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711413892">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tello-Montoliu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marín</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Roldán</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lip</surname>
<given-names>GY</given-names>
</name>
</person-group>. <article-title>The additive value of biomarkers to clinical risk scores in acute coronary syndrome. Are biomarkers really ready for real world usage?</article-title> <source>Heart</source>. <year>2010</year>;<volume>96</volume>(<issue>3</issue>):<fpage>227</fpage>–<lpage>228</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>